Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T

Trial Profile

Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 13 Jul 2017

At a glance

  • Drugs Sipuleucel-T (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms PRIME
  • Sponsors Dendreon Corporation
  • Most Recent Events

    • 06 Jul 2017 Status changed from recruiting to discontinued due to Completion of 3yr follow up.
    • 18 Feb 2017 Preliminary results evaluating the peripheral immune parameters in African American and European American prostate cancer patients receiving Sip-T treatment, presented at the 2017 Genitourinary Cancers Symposium.
    • 06 Oct 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Jan 2022 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top